Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.

Ryan A, Baker A, Dark F, Foley S, Gordon A, Hatherill S, Stathis S, Saha S, Bruxner G, Beckman M, Richardson D, Berk M, Dean O, McGrath J, Group CW, Scott J.

Trials. 2017 Apr 7;18(1):165. doi: 10.1186/s13063-017-1908-5.

2.

Sex differences in the course of schizophrenia across diverse regions of the world.

Novick D, Montgomery W, Treuer T, Moneta MV, Haro JM.

Neuropsychiatr Dis Treat. 2016 Nov 14;12:2927-2939. eCollection 2016.

3.

Are self-stigma, quality of life, and clinical data interrelated in schizophrenia spectrum patients? A cross-sectional outpatient study.

Holubova M, Prasko J, Latalova K, Ociskova M, Grambal A, Kamaradova D, Vrbova K, Hruby R.

Patient Prefer Adherence. 2016 Mar 4;10:265-74. doi: 10.2147/PPA.S96201. eCollection 2016.

4.

The Theory of Industrial Society and Cultural Schemata: Does the "Cultural Myth of Stigma" Underlie the WHO Schizophrenia Paradox?

Pescosolido BA, Martin JK, Olafsdottir S, Long JS, Kafadar K, Medina TR.

AJS. 2015 Nov;121(3):783-825.

5.

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine.

Montgomery W, Kadziola Z, Ye W, Xue HB, Liu L, Treuer T.

Neuropsychiatr Dis Treat. 2015 Jan 19;11:177-83. doi: 10.2147/NDT.S73992. eCollection 2015.

6.

Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia.

Potkin SG, Bugarski-Kirola D, Edgar CJ, Soliman S, Le Scouiller S, Kunovac J, Miguel Velasco E, Garibaldi GM.

CNS Spectr. 2016 Apr;21(2):199-206. doi: 10.1017/S1092852914000352. Epub 2014 Oct 1.

7.

The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan.

Kalache SM, Mulsant BH, Davies SJ, Liu AY, Voineskos AN, Butters MA, Miranda D, Menon M, Kern RS, Rajji TK.

Schizophr Bull. 2015 Mar;41(2):374-81. doi: 10.1093/schbul/sbu114. Epub 2014 Aug 6.

8.

Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.

Ye W, Montgomery W, Kadziola Z, Liu L, Xue H, Stensland MD, Treuer T.

Neuropsychiatr Dis Treat. 2014 May 16;10:869-78. doi: 10.2147/NDT.S59468. eCollection 2014.

9.

The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement.

Mahmoud A, Hayhurst KP, Drake RJ, Lewis SW, Barnes TR.

Ther Adv Psychopharmacol. 2011 Aug;1(4):97-100. doi: 10.1177/2045125311417041.

10.

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey.

Olivares JM, Thirunavukarasu M, Kulkarni J, Zhang HY, Zhang M, Zhang F.

Neuropsychiatr Dis Treat. 2013;9:1163-70. doi: 10.2147/NDT.S49080. Epub 2013 Aug 12.

11.
12.

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

Einarson TR, Geitona M, Chaidemenos A, Karpouza V, Mougiakos T, Paterakis P, Ploumpidis D, Potamitis-Komis D, Zilbershtein R, Vicente C, Piwko C, Kakkavas P, Paparouni K, Jensen RC, Hemels ME.

Ann Gen Psychiatry. 2012 Jul 2;11(1):18. doi: 10.1186/1744-859X-11-18.

13.

Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Harvey PD, Heaton RK, Carpenter WT Jr, Green MF, Gold JM, Schoenbaum M.

Schizophr Res. 2012 Sep;140(1-3):1-8. doi: 10.1016/j.schres.2012.03.025. Epub 2012 Apr 13. Review.

14.

Long term functioning in early onset psychosis: two years prospective follow-up study.

Hassan GA, Taha GR.

Behav Brain Funct. 2011 Jul 30;7:28. doi: 10.1186/1744-9081-7-28.

15.

Cancer and schizophrenia: is there a paradox?

Hodgson R, Wildgust HJ, Bushe CJ.

J Psychopharmacol. 2010 Nov;24(4 Suppl):51-60. doi: 10.1177/1359786810385489. Review.

16.

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.

Kelin K, Brnabic AJ, Newton R, Escamilla RI, Chuo LJ, Simu M, Ye W, Montgomery W, Karagianis J, Ascher-Svanum H.

Patient Prefer Adherence. 2010 Sep 7;4:301-11.

Supplemental Content

Support Center